Nath Bio-Genes (India) credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
139139123105105
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
62.562.533.628.167.2
0.20×0.20×0.19×0.17×0.18×
0.09×0.09×0.05×0.05×0.12×
2.64×2.64×2.46×2.12×2.16×
1.27×1.19×0.67×0.56×1.38×
3.03×3.03×4.39×5.12×4.52×
16.9%16.9%16.0%14.7%15.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATHBIOGEN₹132.38

Nath Bio-Genes (India) Limited

· FMCG & Retail
₹ CrorePeersSARVESHWARINDOUSSUKHJITSKOHINOORAGRITECHREGAALBSHSLGULPOLYMcap ₹252 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt105.2105.5122.5138.5138.5
Net Debt67.228.133.662.562.5
Total Debt/Equity0.180.170.190.200.20
Net Debt/Equity0.120.050.050.090.09
Total Debt/EBITDA2.162.122.462.642.64
Net Debt/EBITDA1.380.560.671.191.27
Interest Coverage (EBIT/Interest)4.525.124.393.033.03
Total Debt/Total Capital %15.5114.7415.9716.9116.91
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.